
Please try another search
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Name | Age | Since | Title |
---|---|---|---|
Louis M. Weiner | 73 | - | Member of Scientific Advisory Board |
Susan Weiss | - | 2020 | Member of COVID-19 Advisory Board |
Andrew D. Badley | - | 2021 | Member of COVID-19 Advisory Board |
Clay B. Siegall | 64 | 2023 | Chairman, President & CEO |
Carol A. Schafer | 61 | 2024 | Independent Director |
Philip Wagenheim | 54 | 2017 | Director |
Shmuel Shoham | - | 2020 | Member of COVID-19 Advisory Board |
Sandra M. Swain | 69 | 2024 | Independent Director |
George C. Prendergast | - | - | Member of Scientific Advisory Board |
James Patrick Boylan | 57 | 2023 | Independent Director |
John M. Lambert | 74 | 2023 | Member of Antibody-Drug Conjugate & T Cell Redirection Advisory Board |
Jean-Jacques Bienaime | 72 | 2023 | Independent Director |
Isaac Barchas | 58 | 2023 | Lead Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review